These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 24272078)

  • 21. Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer.
    Dhillon S
    Drugs; 2013 Apr; 73(5):475-85. PubMed ID: 23529824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
    Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
    Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
    Tesch H; Stoetzer O; Decker T; Kurbacher CM; Marmé F; Schneeweiss A; Mundhenke C; Distelrath A; Fasching PA; Lux MP; Lüftner D; Hadji P; Janni W; Muth M; Kreuzeder J; Quiering C; Taran FA
    Int J Cancer; 2019 Feb; 144(4):877-885. PubMed ID: 29992557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
    Campone M; Bachelot T; Gnant M; Deleu I; Rugo HS; Pistilli B; Noguchi S; Shtivelband M; Pritchard KI; Provencher L; Burris HA; Hart L; Melichar B; Hortobagyi GN; Arena F; Baselga J; Panneerselvam A; Héniquez A; El-Hashimyt M; Taran T; Sahmoud T; Piccart M
    Eur J Cancer; 2013 Aug; 49(12):2621-32. PubMed ID: 23735704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
    Burris HA; Lebrun F; Rugo HS; Beck JT; Piccart M; Neven P; Baselga J; Petrakova K; Hortobagyi GN; Komorowski A; Chouinard E; Young R; Gnant M; Pritchard KI; Bennett L; Ricci JF; Bauly H; Taran T; Sahmoud T; Noguchi S
    Cancer; 2013 May; 119(10):1908-15. PubMed ID: 23504821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis.
    Guo Q; Lin X; Ye L; Xu R; Dai Y; Zhang Y; Chen Q
    Target Oncol; 2019 Apr; 14(2):139-148. PubMed ID: 30941621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Everolimus Plus Letrozole for Treatment of Patients With HR
    Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R
    Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Everolimus plus exemestane in postmenopausal patients with estrogen-receptor-positive advanced breast cancer - Japanese subgroup analysis of BOLERO -2].
    Ito Y; Masuda N; Iwata H; Mukai H; Horiguchi J; Tokuda Y; Kuroi K; Mori A; Ohno N; Noguchi S
    Gan To Kagaku Ryoho; 2015 Jan; 42(1):67-75. PubMed ID: 25596682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
    Jerusalem G; Mariani G; Ciruelos EM; Martin M; Tjan-Heijnen VC; Neven P; Gavila JG; Michelotti A; Montemurro F; Generali D; Simoncini E; Lang I; Mardiak J; Naume B; Camozzi M; Lorizzo K; Bianchetti S; Conte P
    Ann Oncol; 2016 Sep; 27(9):1719-25. PubMed ID: 27358383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.
    Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
    Clin Ther; 2018 Apr; 40(4):628-639.e3. PubMed ID: 29609880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer.
    Wilson FR; Varu A; Mitra D; Cameron C; Iyer S
    Breast Cancer Res Treat; 2017 Nov; 166(1):167-177. PubMed ID: 28752187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endocrine therapies in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer: A network meta-analysis.
    Lee CH; Kang YN; Ho CL; Lin C; Chen PH; Wu YY; Huang TC
    Medicine (Baltimore); 2020 Mar; 99(13):e19618. PubMed ID: 32221087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis.
    Wang J; Xu B; Wang W; Zhai X; Chen X
    Breast Cancer Res Treat; 2018 Oct; 171(3):535-544. PubMed ID: 29974356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.
    Noguchi S; Masuda N; Iwata H; Mukai H; Horiguchi J; Puttawibul P; Srimuninnimit V; Tokuda Y; Kuroi K; Iwase H; Inaji H; Ohsumi S; Noh WC; Nakayama T; Ohno S; Rai Y; Park BW; Panneerselvam A; El-Hashimy M; Taran T; Sahmoud T; Ito Y
    Breast Cancer; 2014 Nov; 21(6):703-14. PubMed ID: 23404211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
    Gnant M; Baselga J; Rugo HS; Noguchi S; Burris HA; Piccart M; Hortobagyi GN; Eakle J; Mukai H; Iwata H; Geberth M; Hart LL; Hadji P; El-Hashimy M; Rao S; Taran T; Sahmoud T; Lebwohl D; Campone M; Pritchard KI
    J Natl Cancer Inst; 2013 May; 105(9):654-63. PubMed ID: 23425564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Jiang Z; Li W; Hu X; Zhang Q; Sun T; Cui S; Wang S; Ouyang Q; Yin Y; Geng C; Tong Z; Cheng Y; Pan Y; Sun Y; Wang H; Ouyang T; Gu K; Feng J; Wang X; Wang S; Liu T; Gao J; Cristofanilli M; Ning Z; Lu X
    Lancet Oncol; 2019 Jun; 20(6):806-815. PubMed ID: 31036468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
    Fribbens C; O'Leary B; Kilburn L; Hrebien S; Garcia-Murillas I; Beaney M; Cristofanilli M; Andre F; Loi S; Loibl S; Jiang J; Bartlett CH; Koehler M; Dowsett M; Bliss JM; Johnston SR; Turner NC
    J Clin Oncol; 2016 Sep; 34(25):2961-8. PubMed ID: 27269946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
    Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
    Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.